Shaperon

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Shaperon is a clinical-stage biotech company with world's first inflammasome inhibitors that regulate both IL-1b and TNF-a. Its' novel MoA of inverse agonism of GPCR-P2X7 axis provides a solution to inherent shortcomings of conventional inflammasome inhibitors

• inverse agonist for GPCR-P2X7 axis
• suppresses not only IL-1b but TNF-a, IL-6, and other major pro-inflammatory cytokines
• overcomes inherent shortcomings of conventional P2X7 antagonists and NLRP3 inhibitors such as off-target effects, polymorphism, and redundant pro-inflammatory pathways etc.
• increases the number of Treg and MDSC(Myeloid-derived Suppressor Cells)
• most advanced development pipelines among peers
Phase 2 in atopic dermatitis
Phase 1 in sepsis
Pre-clinicals in Alzheimer's disease, ulcerative colitis, NASH

Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
NuGel, NuSepin, NuCerin, NuColin
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Shaperon